Researchers at Celera Corporation have developed a biomarker-based serum test to identify lung cancer in people who have never smoked.

To establish the biomarkers, researchers examined more than 600 samples of patients with non-small cell lung cancer.

Once the biomarkers were determined, they conducted additional studies in 80 people who had never smoked, of whom 40 had various stages of cancer histological cell types and 40 were control subjects.

Researchers found that the serum test demonstrated strong performance, with sensitivity and specificity of 83%.

In addition, the test distinguished all stages of lung cancer and histological cell types.

Researchers are planning to conduct further studies to confirm the findings.